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Abstract
Purpose Responsiveness is deﬁned as the ability of an
instrument to accurately detect change when it has occur-
red and is an essential psychometric property of a patient-
reported outcomes (PRO) measure to understand and
interpret study ﬁndings. This study examined the respon-
siveness of 2 Treatment Related Impact Measures
(TRIMs): The TRIM-Diabetes (TRIM-D) and TRIM-Dia-
betes Device (TRIM-DD) as well as conﬁrmed their mea-
surement models in a randomized controlled trial (RCT)
design.
Methods The data were collected in a multi-center, ran-
domized, open-label (2 9 12 week), cross-over study of
two preﬁlled pens in subjects with type 1 or type 2 dia-
betes, age 18 or older. Internal and external responsiveness
were examined. To conﬁrm the measurement model iden-
tiﬁed in the previous study, the Bentler comparative ﬁt
index (CFI) and internal consistency for the RCT sample
scores were examined and compared.
Results Based on a priori criteria, tests of responsiveness
were conﬁrmed with patients having signiﬁcant improve-
ments over time ranging from 2.7 (Psychological Health) to
11.1 (Treatment Burden) (P\0.01) (effect sizes ranging
from 0.2 to 0.8). The previous measurement model factor
structure was conﬁrmed (CFI ranging from 0.8 to 1.0), and
internal consistency of the TRIMs was similar to the
developmental ﬁndings.
Conclusions The total score as well as all domain scores
of the TRIMs was signiﬁcantly responsive over time, thus
acceptable internal and external responsiveness of TRIM-D
and TRIM-DD are concluded. To date, all validation evi-
dence supports the use of these two measures in future
clinical trials.
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PRO Patient-reported outcomes
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RMSEA Root mean square error of approximation
TRIM-D TRIM-Diabetes
TRIM-DD TRIM-Diabetes Device
TS Treatment satisfaction
Introduction
Responsiveness is deﬁned as an instrument’s ability to
accurately detect change that has occurred [1, 2]. Internal
responsiveness is deﬁned as an instrument’s ability to
change during a prespeciﬁed time frame. External
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change corresponds to an external reference value or
measure (assesses an instrument’s ability to reﬂect both
change and no change in the external standard) [3, 4].
This study examined the responsiveness of 2 patient-
reported outcomes (PRO) measures, the Treatment Related
ImpactMeasure-Diabetes(TRIM-D)andTreatmentRelated
Impact Measure-Diabetes Device (TRIM-DD), which were
developed as disease-speciﬁc PRO measures to assess the
impact of diabetes treatment for both type 1 and 2 diabetes
and across the spectrum of pharmacological treatments and
delivery methods [5]. The TRIM-D is a 28 item measure
with 5 domains assessing Treatment Burden, Daily Life,
Diabetes Management, Compliance and Psychological
Health. The TRIM-DD is an 8 item measure with 2 domains
assessing Device Bother and Device Function. Both mea-
sures can be scored independently for each domain or as a
total score. Higher scores indicate a better health state. The
item generation and preliminary validation were conducted
following FDA guidelines for PRO measures development
[1]. Initial validation data for the TRIM-D and TRIM-DD
were collected via an online, cross-sectional survey of 507
USpatients. Thecross-sectionalvalidationshowedthatboth
measures have acceptable psychometric properties [5].
The purpose of the current study was to continue the
validation process by examining the measures’ respon-
siveness and to conﬁrm the measurement model under
randomized controlled trial (RCT) conditions.
Methods
The data used to assess responsiveness came from a multi-
center, randomized, open-label, 2 9 12 week period cross-
over study of two preﬁlled pens in subjects with type 1 or 2
diabetes. All subjects were using insulin by vial/syringe
previous to inclusion in the study and were pen naı ¨ve. Data
for these analyses came from all patients who had com-
pleted the TRIM-D and TRIM-DD at randomization
(baseline) and time of cross-over (week 12). Non-superi-
ority for glucose control between groups was hypothesized.
The study was approved by Sterling IRB (approval #2925),
and all persons gave informed consent.
Analyses
Analyses were conducted according to an a priori statistical
analysis plan. All statistical tests were two-tailed and
conducted with an alpha level of 0.05 as minimal threshold
for signiﬁcance. As the TRIM-D and TRIM-DD are
intended to be used as either a total score or as independent
domains, change scores were examined for both the totals
and domain scores.
Responsiveness analyses
To examine internal responsiveness, t tests were used to
examine differences in TRIM scores between baseline and
week 12 (time of cross-over) with the expectation that
signiﬁcant improvement over time would be shown. Effect
size (ES), measured by Cohen’s d, was examined by cal-
culating the mean change in score divided by the standard
deviation of the mean baseline TRIM score. ES was cate-
gorized: small, 0.2–0.3; medium, 0.4–0.7; and large, 0.8 or
above [6].
External responsiveness was examined by testing the
hypothesis that there will be a linear relationship between
the TRIMs and treatment satisfaction (TS) as assessed by
the insulin treatment satisfaction questionnaire (ITSQ) [7].
The ITSQ, a disease-speciﬁc PRO assessing insulin TS, has
been shown to be reliable and valid [7, 8]. Pearson corre-
lation coefﬁcients between the change in ITSQ overall
summary score (from baseline to week 12) and the change
in each item and domain of the TRIM-D and TRIM-DD
were examined.
Conﬁrmatory analyses of measurement model
A conﬁrmatory factor analysis (CFA) was conducted using
the Bentler comparative ﬁt index (CFI) and root mean
square error of approximation (RMSEA) to determine the
goodness of ﬁt between the models previously identiﬁed
[5] and the current sample data. The criterion used to
indicate acceptable ﬁt was a CFI of at least 0.90 [9] and an
RMSEA of 0.06 [9] or less.
Internal consistency reliability was examined and com-
pared with the original sample with Cronbach’s alpha, a
statistic calculated from the pairwise correlations between
items. Alphas range between zero and one, with coefﬁ-
cients of greater than 0.70 indicating acceptable reliability
[10].
Results
Inthecross-overstudy,242subjectscompletedtheTRIM-D
and TRIM-DD at baseline and week 12 (Table 1).
Responsiveness analyses
Internal responsiveness
AllTRIM-DandTRIM-DDdomainsandoveralltotalscores
andmostindividualitems(TRIM-D:23/28;TRIM-DD:6/8)
changed signiﬁcantly after 12 weeks of randomized treat-
ment. For the Treatment Burden, Diabetes Management,
Daily Life, and total TRIM-D, these signiﬁcant change
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Psychological Health and Compliance domains, the signif-
icant change scores were associated with a small ES. Score
changes ranged from 18.6 (ES 0.84, TRIM-D Treatment
Burden) to 3.1 (ES 0.17, TRIM-D Psychological Health).
For the TRIM-DD domains and total score, large changes
(9.4–10.1) along with moderate ES (0.43–0.56) were seen
(Table 2).
External responsiveness
Strong associations were found between the ITSQ change,
TRIM-D Total score (r = 0.72, P\0.001) and TRIM-DD
Total score (r = 0.68, P\0.001). Moderate to strong
correlations were noted between the ITSQ overall summary
score and items from the domains: Treatment Burden
(r ranging between 0.32 and 0.53), Daily Life (0.37–0.45),
Diabetes Management (0.22–0.38), Psychological Health
(0.35–0.51), Device Function (0.30–0.51), and Device
Bother (0.40–0.57). Lower associations were noted between
ITSQ score and the Compliance domain (0.14–0.25).
Conﬁrmatory measurement model analyses
Fit statistics
The model ﬁt statistics for the TRIM-D and TRIM-DD
Total domains were conﬁrmed and are presented in
Table 3.
Table 1 Sample description
Age Mean (SD)
(n = 242)
58.0 (13.9)
Range 22–87
Gender N (%) Male 147 (60.7%)
N (%) Female 95 (39.3%)
Body mass index (BMI) at
randomization
Mean (SD)
(n = 242)
31.4 (6.1)
Range
18.7–44.9
Diabetes type N (%) Type 1 70 (28.9%)
N (%) Type 2 172 (71.1%)
HbA1c at randomization Mean (SD)
(n = 240)
7.3 (0.9)
Range
5.2–10.2
Ethnicity N (%) White 199 (82.2%)
N (%) Black 29 (12.0%)
N (%) Asian 7 (2.9%)
N (%) Other 7 (2.9%)
Table 2 Responsiveness of the TRIM-Diabetes and TRIM-Diabetes Device items and domains
Baseline Week 12 Change
score
Abbreviated item content Mean (SD) Mean (SD) Mean (SD) t-stat Effect
size
a
ITSQ overall
summary
(Pearson r)
TRIM-Diabetes TOTAL SCORE (n = 226) 65.9 (15.0) 74.2 (13.0) 8.3 (13.5) 9.2*** 0.55 0.72**
Treatment Burden (n = 225) 54.7 (22.1) 73.3 (19.2) 18.6 (25.0) 11.1*** 0.84 0.58**
The ease and convenience of your medication 3.4 (0.8) 4.0 (0.9) 0.6 (1.1) 8.7*** 0.75 0.53**
Carry your medication and supplies around with you 2.8 (1.2) 3.7 (1.0) 1.0 (1.4) 10.2*** 0.75 0.48**
Store your medication 3.2 (1.2) 4.0 (1.0) 0.8 (1.4) 8.1*** 0.67 0.44**
Take your medication at the right time 3.3 (1.1) 3.9 (0.9) 0.65 (1.3) 7.5*** 0.55 0.44**
Prepare your medication for use 3.4 (1.1) 4.2 (0.9) 0.8 (1.4) 9.0*** 0.73 0.51**
Monitor your blood sugar as often as necessary 3.1 (1.1) 3.7 (1.0) 0.6 (1.2) 7.9*** 0.55 0.32**
Daily Life (n = 226) 68.4 (18.5) 75.6 (16.8) 7.2 (17.9) 6.0*** 0.39 0.58**
Meal time planning 3.6 (0.9) 4.0 (0.9) 0.4 (1.0) 6.1*** 0.44 0.45**
Social activities 3.5 (1.1) 4.0 (0.9) 0.5 (1.1) 6.3*** 0.45 0.45**
Do you have to limit your daily activities? 4.0 (0.8) 4.2 (0.8) 0.2 (1.0) 2.5* 0.25 0.39**
Do you accomplish less than you would like to? 3.5 (1.1) 3.8 (1.0) 0.2 (1.1) 3.3** 0.27 0.37**
Do you feel tension in your relationships with friends or
family?
4.1 (0.9) 4.3 (0.9) 0.15 (1.0) 2.4* 0.22 0.39**
Diabetes Management (n = 226) 52.5 (19.2) 61.7 (17.9) 9.3 (19.2) 7.2*** 0.48 0.43**
Help you control your diabetes 3.3 (0.9) 3.7 (0.8) 0.35 (1.0) 5.1*** 0.44 0.38**
Help you avoid high blood sugar (hyperglycemia) 3.2 (1.0) 3.6 (0.9) 0.4 (1.2) 5.0*** 0.40 0.34**
Help you avoid low blood sugar (hypoglycemia) 3.4 (0.9) 3.8 (0.8) 0.35 (0.9) 5.7*** 0.44 0.31**
Help you manage your weight 2.7 (1.2) 3.0 (1.1) 0.35 (1.1) 4.8*** 0.30 0.22**
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n CFI RMSEA
Chi-Square (Sig.) df
TRIM-Diabetes total (28 items) 222 0.955 0.031 3602.4 (P\0.001) 378
Treatment Burden (6 items) 235 0.972 0.020 763.7 (P\0.001) 15
Daily Life (5 items) 235 0.818 0.072 447.6 (P\0.001) 10
Diabetes Management (5 items) 235 0.888 0.051 498.2 (P\0.001) 10
Compliance (4 items) 235 0.988 0.018 310.9 (P\0.001) 6
Psychological (8 items) 229 0.948 0.037 923.5 (P\0.001) 28
Table 2 continued
Baseline Week 12 Change
score
Abbreviated item content Mean (SD) Mean (SD) Mean (SD) t-stat Effect
size
a
ITSQ overall
summary
(Pearson r)
Help you prevent feeling tired or a lack of energy 2.8 (1.0) 3.3 (1.1) 0.4 (1.0) 6.3*** 0.50 0.31**
Compliance (n = 226) 75.7 (17.0) 79.3 (15.0) 3.7 (15.1) 3.7*** 0.22 0.30**
Miss a dose 4.3 (0.7) 4.4 (0.7) 0.1 (0.7) 2.5** 0.14 0.21**
Delay or postpone taking your medication 3.9 (0.9) 4.1 (0.8) 0.2 (0.8) 3.3** 0.22 0.14*
Take your medication at a different time than prescribed 3.9 (0.9) 4.1 (0.8) 0.1 (1.0) 2.2* 0.22 0.23**
Worry that you forgot to take/or missed your last dose of
medication
4.0 (0.9) 4.2 (0.8) 0.2 (1.0) 2.5* 0.22 0.25**
Psychological Health (n = 221) 76.2 (18.6) 79.2 (17.2) 3.1 (16.9) 2.7** 0.17 0.59**
Depressed 4.3 (0.9) 4.4 (0.9) 0.1 (0.8) 1.5 (P = 0.137) 0.11 0.36**
Worried that the medication is not helping to slow down or
prevent complications from my diabetes
3.9 (1.0) 4.0 (1.0) 0.1 (1.1) 0.7 (P = 0.494) 0.10 0.44**
Nervous or anxious 4.2 (0.8) 4.4 (0.8) 0.1 (0.9) 2.2* 0.25 0.41**
Worried about my blood sugar control 3.4 (1.1) 3.5 (1.0) 0.1 (1.1) 1.7 (P = 0.084) 0.09 0.47**
Unhealthy 4.1 (1.0) 4.1 (1.0) 0.05 (1.0) 0.8 (P = 0.434) 0.00 0.40**
Angry 4.3 (1.0) 4.4 (0.9) 0.05 (0.9) 0.8 (P = 0.417) 0.10 0.35**
Worried about side effects from my medication 3.9 (1.1) 4.2 (1.0) 0.25 (1.1) 3.2** 0.27 0.38**
Feel embarrassed or awkward when taking your medication 4.3 (0.9) 4.5 (0.7) 0.2 (0.9) 3.8*** 0.22 0.51**
TRIM-Diabetes Device TOTAL SCORE (n = 214) 72.2 (17.1) 81.8 (15.2) 9.6 (20.6) 6.9*** 0.56 0.68**
Device Function (n = 214) 71.6 (18.5) 81.0 (17.0) 9.4 (22.7) 6.0*** 0.51 0.56**
Learn how to use your device 3.9 (0.9) 4.4 (0.8) 0.6 (1.1) 7.3*** 0.56 0.47**
Keep your device functioning properly 4.1 (0.8) 4.4 (0.8) 0.3 (1.1) 4.2*** 0.38 0.42**
Adjust your medication for small dose changes 3.8 (1.0) 4.4 (0.9) 0.6 (1.4) 6.4*** 0.60 0.51**
That your device delivers the correct, full dose of your
medication
3.7 (1.0) 3.8 (1.1) 0.2 (1.4) 1.7 (P = 0.094) 0.10 0.34**
That you are using the device properly 4.0 (0.9) 4.2 (1.0) 0.2 (1.2) 2.8** 0.22 0.30**
Device Bother (n = 214) 73.2 (23.3) 83.3 (19.5) 10.1 (26.1) 5.6*** 0.43 0.64**
Size of your device 4.3 (0.9) 4.4 (0.9) 0.1 (1.2) 1.8 (P = 0.076) 0.11 0.40**
Physical discomfort related to using your device 3.9 (1.0) 4.4 (0.9) 0.5 (1.2) 5.5*** 0.50 0.55**
Using your device in public 3.6 (1.4) 4.2 (1.1) 0.6 (1.4) 6.1*** 0.43 0.57**
TRIM Treatment Related Impact Measure, SD Standard deviation, ITSQ Insulin treatment satisfaction questionnaire
a Effect size = mean change in score divided by the standard deviation of mean baseline score
*** Correlation is signiﬁcant at the 0.001 level (2-tailed)
** Correlation is signiﬁcant at the 0.01 level (2-tailed)
* Correlation is signiﬁcant at the 0.05 level (2-tailed)
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All alphas for the TRIM-D and TRIM-DD (overall score
and all domains) were above 0.70 indicating acceptable
internal consistency. Additionally, the conﬁrmatory RCT
sample alphas were similar to the development coefﬁcients
(within 0.1).
Discussion
These analyses found that the TRIMs total scores as well as
all domain scores were signiﬁcantly responsive over time
and had the ability to differ between levels of change of an
external criterion. Thus, internal and external responsive-
ness for the TRIM-D and TRIM-DD have been conﬁrmed
in an RCT sample. The measurement model was conﬁrmed
for all domains with lower than expected ﬁt statistics for
the Daily Life and Diabetes Management domains. Given
that these domains were shown to have a strong factor
structure in the development of the measures [3], this
ﬁnding may be speciﬁc to this trial design or sample.
Further testing the TRIM-D domain structure in other trials
is warranted to conﬁrm these ﬁndings.
The total score and all domain scores of the TRIMs were
signiﬁcantly responsive over time with the Treatment
Burden domain showing the greatest responsiveness and
the Psychological Health domain the least responsiveness.
Additionally, the greatest number of individual items
which were not responsive over time came from the Psy-
chological Health domain. These ﬁndings should be
interpreted in light of the study’s nature. Given that all
patients received the same insulin treatment, it is under-
standable that the psychological component of treatment,
which is often driven by treatment efﬁcacy, would be the
least responsive. However, the fact that the overall Psy-
chological Health domain was still signiﬁcant as an overall
concept and suggests that insulin pen delivery system does
contribute positively to the psychological impact of
treatment.
As expected, given that the study was a device cross-
over with non-superiority for drug effect, the Treatment
Burden domain, the domain which should be most
impacted by delivery mode, was the most responsive
domain. These ﬁndings underscore the importance of
understanding the independent contribution of domains,
given the speciﬁc study design and hypotheses, in order to
optimally identify, a priori, domains of a measure which
will be responsive to change. As the TRIMs were devel-
oped and validated for stand-alone use of each domain as
well as the total score, future use of the TRIMs can and
should take independent domain responsiveness into con-
sideration when making these a priori hypotheses.
Certain study limitations should be considered in inter-
preting results. To assess external validity, the ITSQ, a PRO
measure rather than a clinical measure, was used as the
reference value. It was not possible to use a clinical refer-
encevalueduetotwofactors.First,HbA1cB9%wasastudy
eligibility criterion and the majority of patients entered the
studyingoodoradequateHbA1ccontrol(61%,\7.5).Thus,
there could only be a limited number of patients who could
change from inadequate to adequateglucose control.In fact,
in this sample, there were only 11 patients (4.8%) who
changed from randomization poor control ([7.0%) to ade-
quate control over the 12-week period (\7.0%). Second, the
study was designed as a non-inferiority trial to examine
difference in insulin delivery mode rather than drug treat-
ment efﬁcacy, and all patients received the same insulin
treatment during the study. Thus, no differences in glucose
control were expected or found. As a result of these design
features, there was not an adequate size sample of patients
who had a signiﬁcant improvement or worsening of HbA1c
to conduct responsiveness analyses using a clinical refer-
ence value. Further, the fact that a majority of these patients
were in good control at study start may limit the external
generalizability of ﬁndings.
Validation is an iterative process. This study continues
that process for the TRIM-Diabetes and TRIM-Diabetes
Device measures. To date, all evidence supports the use of
these measures in future clinical trials.
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Table 3 continued
n CFI RMSEA
Chi-Square (Sig.) df
TRIM-Diabetes Device total (8 items) 226 1.000 0.000 722.6 (P\0.001) 28
Device Function (5 items) 226 1.000 0.000 476.9 (P\0.001) 10
Device Bother (3 items) 227 1.000 0.000 181.7 (P\0.001) 3
CFI Comparative ﬁt index, RMSEA Root mean square error of approximation, df degrees of freedom
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